Mucosal immunization with newcastle disease virus vector coexpressing HIV-1 env and gag proteins elicits potent serum, mucosal, and cellular immune responses that protect against vaccinia virus env and gag challenges

mBio

Volumn 6, Issue 4, 2015, Pages

  Khattar, Sunil K ^a   Manoharan, Vinoth ^a   Bhattarai, Bikash ^a   Labranche, Celia C ^b   Montefiori, David C ^b   Samal, Siba K ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 160; VIRUS VECTOR; DRUG CARRIER; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT VACCINE; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MALE; MOUSE; MUCOSAL IMMUNITY; NEWCASTLE DISEASE VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINIA VIRUS; VIRUS ENVELOPE; VIRUS LIKE AGENT; VIRUS RECOMBINANT; VIRUS REPLICATION; ANIMAL; BLOOD; DISEASE MODEL; GENE VECTOR; GENETICS; GUINEA PIG; IMMUNOLOGY; MUCOSAL DRUG ADMINISTRATION; SERUM; VACCINIA;

ADMINISTRATION, MUCOSAL; AIDS VACCINES; ANIMALS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VECTORS; GUINEA PIGS; HIV ANTIBODIES; HIV-1; IMMUNITY, CELLULAR; MICE; NEWCASTLE DISEASE VIRUS; SERUM; VACCINES, SYNTHETIC; VACCINIA; VACCINIA VIRUS;

EID: 84940870885     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01005-15     Document Type: Article

References (37)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH, MOPH-TAVEG Investigators. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209–2220. http://dx.doi.org/10.1056/NEJMoa0908492
2. McElrath MJ, Haynes BF. 2010. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33:542–554. http://dx.doi.org/10.1016/j.immuni.2010.09.011
3. Hammonds J, Chen X, Zhang X, Lee F, Spearman P. 2007. Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines. Vaccine 25:8036–8048. http://dx.doi.org/10.1016/j.vaccine.2007.09.016
4. Young KR, McBurney SP, Karkhanis LU, Ross TM. 2006. Virus-like particles: designing an effective AIDS vaccine. Methods 40:98–117. http://dx.doi.org/10.1016/j.ymeth.2006.05.024
5. Sakuragi S, Goto T, Sano K, Morikawa Y. 2002. HIV type 1 Gag virus-like particle budding from spheroplasts of Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 99:7956–7961. http://dx.doi.org/10.1073/pnas.082281199
6. Hammonds J, Chen X, Fouts T, DeVico A, Montefiori D, Spearman P. 2005. Induction of neutralizing antibodies against human immunodefi- ciency virus type 1 primary isolates by Gag-Env pseudovirion immunization. J Virol 79:14804–14814. http://dx.doi.org/10.1128/JVI.79.23.14804-14814.2005
7. McBurney SP, Ross TM. 2009. Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines. Vaccine 27:4337–4349. http://dx.doi.org/10.1016/j.vaccine.2009.04.032
8. Fang ZY, Kuli-Zade I, Spearman P. 1999. Efficient human immunode- ficiency virus (HIV)-1 Gag-Env pseudovirion formation elicited from mammalian cells by a canarypox HIV vaccine candidate. J Infect Dis 180: 1122–1132. http://dx.doi.org/10.1086/315028
9. Young KR, Smith JM, Ross TM. 2004. Characterization of a DNA vaccine expressing a human immunodeficiency virus-like particle. Virology 327: 262–272. http://dx.doi.org/10.1016/j.virol.2004.07.009
10. Lamb RA, Park GD. 2007. Paramyxoviruses: the viruses and their replication, p 144–196. In Knipe DM, Lamb RA, Martin MA, Rioizman B, Strauss SE (ed), Field’s virology, 5th ed. Lippincott Williams and Wilkins, Philadelphia, PA
11. Bukreyev A, Collins PL. 2008. Newcastle disease virus as a vaccine vector for humans. Curr Opin Mol Ther 10:46–55
12. Fournier P, Schirrmacher V. 2013. Oncolytic Newcastle disease virus as cutting edge between tumor and host. Biology (Basel) 2:936–975. http://dx.doi.org/10.3390/biology2030936
13. Bukreyev A, Huang Z, Yang L, Elankumaran S, St Claire M, Murphy BR, Samal SK, Collins PL. 2005. Recombinant Newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol 79:13275–13284. http://dx.doi.org/10.1128/JVI.79.21.13275-13284.2005
14. DiNapoli JM, Kotelkin A, Yang L, Elankumaran S, Murphy BR, Samal SK, Collins PL, Bukreyev A. 2007. Newcastle disease virus, a host rangerestricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc Natl Acad Sci U S A 104:9788–9793. http://dx.doi.org/10.1073/pnas.0703584104
15. DiNapoli JM, Yang L, Suguitan A, Jr, Elankumaran S, Dorward DW, Murphy BR, Samal SK, Collins PL, Bukreyev A. 2007. Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus. J Virol 81:11560–11568. http://dx.doi.org/10.1128/JVI.00713-07
16. DiNapoli JM, Nayak B, Yang L, Finneyfrock BW, Cook A, Andersen H, Torres-Velez F, Murphy BR, Samal SK, Collins PL, Bukreyev A. 2010. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol 84:1489–1503. http://dx.doi.org/10.1128/JVI.01946-09
17. DiNapoli JM, Yang L, Samal SK, Murphy BR, Collins PL, Bukreyev A. 2010. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine 29:17–25. http://dx.doi.org/10.1016/j.vaccine.2010.10.024
18. Khattar SK, Samal S, Devico AL, Collins PL, Samal SK. 2011. Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs. J Virol 85:10529–10541. http://dx.doi.org/10.1128/JVI.05050-11
19. Xiao S, Kumar M, Yang X, Akkoyunlu M, Collins PL, Samal SK, Pal U. 2011. A host-restricted viral vector for antigen-specific immunization against Lyme disease pathogen. Vaccine 29:5294–5303. http://dx.doi.org/10.1016/j.vaccine.2011.05.010
20. Khattar SK, Samal S, LaBranche CC, Montefiori DC, Collins PL, Samal SK. 2013. Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated Newcastle disease virus vector. PLoS One 8:e78521. http://dx.doi.org/10.1371/journal.pone.0078521
21. Kim SH, Chen S, Jiang X, Green KY, Samal SK. 2014. Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice. J Virol 88:9718–9727. http://dx.doi.org/10.1128/JVI.01570-14
22. Khattar SK, Palaniyandi S, Samal S, LaBranche CC, Montefiori DC, Zhu X, Samal SK. 2015. Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus. Hum Vaccin Immunother 11:504–515. http://dx.doi.org/10.4161/21645515.2014.987006
23. Wyatt R, Sodroski J. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280:1884–1888. http://dx.doi.org/10.1126/science.280.5371.1884
24. Guerbois M, Moris A, Combredet C, Najburg V, Ruffié C, Février M, Cayet N, Brandler S, Schwartz O, Tangy F. 2009. Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic. Virology 388:191–203. http://dx.doi.org/10.1016/j.virol.2009.02.047
25. Haglund K, Forman J, Kräusslich HG, Rose JK. 2000. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope. Virology 268: 112–121. http://dx.doi.org/10.1006/viro.1999.0120
26. Zhao H, Peeters BP. 2003. Recombinant Newcastle disease virus as a viral vector: effect of genomic location of foreign gene on gene expression and virus replication. J Gen Virol 84:781–788. http://dx.doi.org/10.1099/vir.0.18884-0
27. Carnero E, Li W, Borderia AV, Moltedo B, Moran T, García-Sastre A. 2009. Optimization of human immunodeficiency virus gag expression by Newcastle disease virus vectors for the induction of potent immune responses. J Virol 83:584–597. http://dx.doi.org/10.1128/JVI.01443-08
28. Zhu P, Liu J, Bess J, Jr, Chertova E, Lifson JD, Grisé H, Ofek GA, Taylor KA, Roux KH. 2006. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441:847–852. http://dx.doi.org/10.1038/nature04817
29. Toapanta FR, Craigo JK, Montelaro RC, Ross TM. 2007. Reduction of anti-HIV-1 Gag immune responses during co-immunization: immune interference by the HIV-1 envelope. Curr HIV Res 5:199–209. http://dx.doi.org/10.2174/157016207780077057
30. Van Montfort T, Sanders RW. 2012. Optimizing cellular immunity against HIV-1 Gag and preventing suppression by HIV-1 gp120. Expert Rev Vaccines 11:1175–1177. http://dx.doi.org/10.1586/erv.12.102
31. Böckl K, Wild J, Bredl S, Kindsmüller K, Köstler J, Wagner R. 2012. Altering an artificial Gagpolnef polyprotein and mode of ENV coadministration affects the immunogenicity of a cladeCHIVDNAvaccine. PLoS One 7:e34723. http://dx.doi.org/10.1371/journal.pone.0034723
32. Bonsignori M, Moody MA, Parks RJ, Holl TM, Kelsoe G, Hicks CB, Vandergrift N, Tomaras GD, Haynes BF. 2009. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J Immunol 183: 2708–2717. http://dx.doi.org/10.4049/jimmunol.0901068
33. Gallo RC. 2005. The end or the beginning of the drive to an HIVpreventive vaccine: a view from over 20 years. Lancet 366:1894–1898. http://dx.doi.org/10.1016/S0140-6736(05)67395-3
34. Pulendran B, Ahmed R. 2011. Immunological mechanisms of vaccination. Nat Immunol 12:509–517. http://dx.doi.org/10.1038/ni.2039
35. McDermott AB, Koup RA. 2012. CD8(+) T cells in preventing HIV infection and disease. AIDS 26:1281–1292. http://dx.doi.org/10.1097/QAD.0b013e328353bcaf
36. Hersperger AR, Migueles SA, Betts MR, Connors M. 2011. Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control. Curr Opin HIV AIDS 6:169–173. http://dx.doi.org/10.1097/COH.0b013e3283454c39
37. Maamary J, Array F, Gao Q, García-Sastre A, Steinman RM, Palese P, Nchinda G. 2011. Newcastle disease virus expressing a dendritic celltargeted HIV gag protein induces a potent gag-specific immune response in mice. J Virol 85:2235–2246. http://dx.doi.org/10.1128/JVI.02036-10.